Second-generation antipsychotics (SGAs) are the cornerstone of treatment for schizophrenia
because of their high clinical efficacy. However, SGA treatment is associated with severe …

Rationale Multiple drugs are known to induce metabolic malfunctions, among them second-
generation antipsychotics (SGAs). The pathogenesis of such adverse effects is of …

Background Social determinants of health (SDoHs) are nonmedical factors that significantly
impact health and longevity. We found no published reviews on the biology of SDoHs in …

Antipsychotics frequently cause obesity and related metabolic disorders that current
psychopharmacological/endocrinological theories do not explain consistently. An …

Background To explore the influence of CYP2D6 genetic polymorphism on risperidone
metabolism, thereby affecting risperidone's effects and safeties in patients with chronic …

Antipsychotics increase weight, BMI and waist size, particularly in pediatric patients.
Switching antipsychotics is common practice, thus defining the risk for each antipsychotic in …

Objectives To report the distribution and predictors of insulin resistance (IR) in young people
presenting to primary care-based mental health services. Design Cross-sectional. Setting …

Objectif: Les effets métaboliques indésirables potentiels des antipsychotiques de deuxième
génération (ADG) doivent être sous surveillance. L'Alliance canadienne pour la surveillance …

Los agentes antipsicóticos son considerados como el principal tratamiento farmacológico
para el manejo de mantenimiento y el tratamiento de casos agudos de la esquizofrenia y …

Aims The risk of antipsychotic-associated cardiovascular and metabolic events may differ
among countries, and limited real-world evidence has been available comparing the …